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Abstract: Psoriasis is one of the most common chronic, inflammatory, T-cell-mediated 
autoimmune diseases. Over the past decade, increased knowledge of disease pathogenesis has 
fundamentally changed psoriasis treatment, with the introduction of biologics, and this has led 
to a multitude of improved selective targets providing potential therapeutic options. Indeed, 
numerous pathogenesis-based treatments are currently in development, as psoriasis has also 
become increasingly relevant for proof-of-concept studies. The purpose of this review was to 
summarize current knowledge of psoriasis immunopathogenesis, focusing on the T-cell-mediated 
immune response and its initiation. The authors describe recent advances in psoriasis treatment 
and discuss pathogenesis-based therapies that are currently in development or which could be 
envisioned for the future. Although current biologics are well tolerated, several issues such as 
long-term efficacy, long-term safety, and high costs keep driving the search for new and better 
therapies. With further advances in understanding disease pathogenesis, more genomic data 
from psoriasis patients becoming available, and potentially the identification of autoantigens 
in psoriasis, current research should lead to the development of a growing arsenal of improved 
targeted treatments and to further breakthrough immunotherapies.
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Introduction
Psoriasis is a chronic, inflammatory, T-cell-mediated autoimmune disease that affects 
mainly skin and joints. It is one of the most common inflammatory skin diseases, 
affecting 2%–3% of the population. Psoriasis is characterized by the presence of 
sharply demarcated, red plaques with adherent silvery-white scales and a tendency for 
symmetrical distribution over the body. The clinical presentation is mirrored histologi-
cally by dramatic hyperplasia of the epidermis (acanthosis) with loss of the granular 
layer, regular elongation of the rete ridges (papillomatosis), thickening of the corneal 
layer (hyperkeratosis), and incomplete keratinocyte differentiation with retention of 
nuclei in the stratum corneum (parakeratosis). The inflammatory infiltrate is made 
up mainly of macrophages, different types of dendritic cells, and T cells within the 
dermis, as well as neutrophils and some T cells in the epidermis. The redness of the 
lesions is caused by an increased vascularity – an increased number of dilated and 
tortuous capillaries in the dermal papillae.
However, psoriasis does not affect skin and joints only. It is a multisystem disease 
associated with a multitude of comorbidities and thus psoriasis has become increas-
ingly important for all medical fields, beyond just dermatology and rheumatology. 
Psoriasis patients show an increased risk for cardiovascular events.1,2 The prevalence 
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of metabolic syndrome – a combination of obesity, dyslipi-
demia, impaired glucose regulation, and hypertension – is 
elevated in psoriasis patients.3 The prevalence of depression 
is increased, and psoriasis can have a substantial psycho-
logical impact on patients.4,5 In addition to this, psoriasis is 
often associated with other immune-mediated inflammatory 
disorders. Intriguingly, chronic inflammatory bowel disease, 
diabetes, and psoriasis have been associated with the same or 
similar susceptibility genes.6,7 Although the mechanisms of 
inheritance are still poorly understood, nowadays psoriasis 
is accepted as a genetic disease with a complex interplay of 
genetic and environmental factors providing the basis for 
disease development.
Over the past decade, psoriasis has become more and 
more important as a model disease for scientists working on 
chronic inflammation and autoimmunity. Psoriasis has also 
become increasingly relevant as a first-choice disease for 
proof-of-concept studies investigating the efficacy of newer 
pathogenesis-based treatments.
The purpose of this review was to summarize current 
knowledge of psoriasis immunopathogenesis, focusing on 
the T-cell-mediated immune response and its initiation. This 
review will span a bridge from pathogenesis of psoriasis and 
its classical treatment to the new avenues of biologics – the 
authors describe recent advances in psoriasis treatment and 
discuss pathogenesis-based therapies that are currently in 
development or which could be envisioned for the future.
Pathogenesis
As clinical appearance is characterized by hyperkeratosis 
and silvery-white scales due to hyperproliferating keratino-
cytes, for a long time psoriasis was considered a keratinocyte 
disease. Only the effective use of cyclosporin A in psoriasis 
patients in the late 1970s8 and therapeutic agents targeting 
T cells but not keratinocytes (eg, DAB389IL-2, anti-CD4)9,10 
led to a paradigm shift from epidermal keratinocytes to vari-
ous immunocyte populations. Nevertheless, the discussion 
about the primary instigator of psoriasis is still  ongoing. 
Recent evidence from mouse models and translational 
research strongly indicates that psoriasis is actually caused 
by a combination of both a primary defect in keratinocytes 
and an inappropriate innate and adaptive immune response–
driven type I interferon (IFN) and that it is mediated mainly 
by resident and infiltrating T cells (Figure 1).11–14
In individuals with a genetic predisposition, external 
stimuli such as trauma (known as Koebner phenomenon), 
infections, stress, drugs, and alcohol can all trigger an initial 
episode of psoriasis. This initial trigger activates the innate 
immune system. Complexes of the antimicrobial peptide 
LL-37 and host DNA/RNA, both released by keratinocytes 
after common epidermal damage, activate plasmacytoid 
dendritic cells (pDCs) to produce large amounts of IFN.13,15 
Physiologically, pDCs are sensors of viral nucleic acid and 
induce protective immunity.16 In psoriasis, IFN produc-
tion by pDCs is an early key event in disease development 
by driving autoimmunity. IFN induces the activation and 
maturation of conventional dendritic cells (cDCs), which are 
key stimulators of T cells, thereby bridging the gap between 
innate and adaptive immunity.12 Subsequently, autoreactive 
T cells proliferate and migrate into the epidermis, another 
key event in psoriasis pathogenesis and controlled by the 
expression of alpha 1 beta 1 integrin on effector T cells.14 This 
T-cell expansion and migration into the epidermis precedes 
the onset of psoriasis and is essential for the development 
of characteristic epidermal changes. Although the putative 
(epidermal) autoantigen in psoriasis remains elusive, T cells 
show oligoclonal expansion, indicating a common antigen 
for autoimmune T cells.17,18 In psoriasis, these autoreactive 
T cells are IFN-gamma-secreting type 1 T helper (Th1) 
cells19 and Th17/Th22 cells producing interleukin (IL)-17 
and IL-22.20,21 Th1 and Th17 cells seem to show concomitant 
presence in various inflammatory pathologies, but they – 
along with Th22 cells – represent distinctly polarized Th cell 
types.22–24 Research has recently focused on Th17/Th22 cells 
and IL-23,25–27 which induces IL-17 and IL-22 production by 
T cells.28 These cytokines are key mediators linking adaptive 
immune response and epithelial dysregulation in psoriasis.29,30 
IL-22 induces hyperproliferation of keratinocytes (leading 
to typical acanthosis), and both IL-17 and IL-22 increase 
production of the antimicrobial peptide LL-37.31–33 In turn, 
the increased LL-37 production leads to continuous activation 
of the immune system, as described earlier. Therefore, these 
cytokines potentially not only cause the typical epidermal 
changes seen in psoriasis but also lead to a self-sustained 
feedback loop and chronification of the disease.34 Indeed, in 
contrast to the transient skin expression of LL-37 in response 
to skin injury in healthy individuals,35 high levels of LL-37 
appear to persist in psoriatic skin lesions. Subsequently, the 
maintained production of IFN leads to uncontrolled activation 
of cDCs and eventually to autoimmunity.
Interestingly, IFN has recently been shown to specifi-
cally upregulate IL-22-receptor expression on keratinocytes 
and thereby increase responsiveness to IL-22.36 Thus, in 
psoriasis pathogenesis, IFN seems to have multiple roles: 
it drives immune activation with the induction of IL-22- 
(and IL-17-) producing T cells through cDC activation and 
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IL-23  induction; in addition, it provides the interface between 
immune activation and epidermal remodeling by increasing 
keratinocyte responsiveness to IL-22.36,37 Intriguingly, IL-22 
was indeed shown to be critical for the imiquimod mouse 
model, in which Toll-like receptor 7/8 activation induces 
IFN-driven psoriasiform skin inflammation.38 A third poten-
tial effect of IFN could be an enhanced expression of major 
histocompatibility complex class I on keratinocytes, which 
may promote presentation of putative autoantigens to intra-
epidermal T cells.39 In psoriasis, this may lead to enhanced 
activation of pathogenic autoimmune T cells.
Taken together, a sustained LL-37-IFN-Th17/Th22 
axis seems to be crucial for psoriasis pathogenesis. 
 Intriguingly, several genetic variants that have been associ-
ated with psoriasis provide a direct genetic basis for this 
axis; these  susceptibility genes include RAGE and IFN 
regulatory  factor 540 (involved in activation of pDCs and 
IFN induction),  certain major histocompatibility complex 
class I molecules40,41 (involved in autoantigen presentation 
and activation of T cells), gene polymorphisms of IL-23 
and IL-23 receptor42,43 (involved in Th17 polarization and 
expansion), and gene copy number polymorphisms of anti-
microbial peptides.44
In addition to the well-established role for conventional 
T cells in psoriasis pathogenesis already described in this 
review, recent studies have indicated a potential contribu-
tion of innate gamma-delta (γδ) T cells. Dermal γδ T cells 
constitutively express IL-23 receptor and rapidly produce 
large amounts of IL-17 upon stimulation with IL-23.45–47 
Thereby, γδ T cells may amplify Th17 responses and induce 
autoimmunity.45 Intriguingly, in the imiquimod mouse 
model, γδ T cells were essential and sufficient to induce 
psoriasiform skin inflammation.46,48 Although relevance for 
human disease remains to be shown, γδ T cells accumulate 
in psoriasis plaques and this indicates a possible functional 
role in psoriasis pathogenesis.46 This hypothesis is further 
supported by the identification of a novel proinflammatory 
Vγ9Vδ2 T-cell subset that is rapidly recruited into psoriatic 
skin and potentially mediates an immediate tissue response 
upon koebnerization.49 Similarly, natural killer (NK) cells and 
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Figure 1 Psoriasis pathogenesis: upon skin injury, known as koebnerization, antimicrobial peptides (AMPs) such as LL-37 produced by keratinocytes or deposited by 
infiltrating neutrophils form complexes with self-nucleic acids (DNA and RNA) released by dying cells.
Notes: These complexes are transported into intracellular compartments, leading to the activation of plasmacytoid dendritic cells (pDCs) via endosomal Toll-like receptors 
7 and 9 and thereby leading to the production of type I interferons (IFN alpha [IFN-α], IFN beta [IFN-β]) early in psoriasis pathogenesis. Subsequently, type I IFNs trigger 
maturation and differentiation of conventional dendritic cells (cDCs), and these cDCs then stimulate autoreactive T cells through interleukin (iL)-23. Thereby, psoriatic 
autoimmune T cells are biased to produce T helper (Th)17 cytokines iL-17 and iL-22. interestingly, these cytokines induce expression of AMPs in keratinocytes, suggesting a 
positive feedback loop that further sustains innate activation of pDCs and leads to type I IFN-driven autoimmunity. In addition, type I IFNs directly upregulate IL-22 receptor 
(iL-22R) on keratinocytes, increasing their responsiveness to iL-22, which inhibits terminal differentiation and induces hyperproliferation of keratinocytes leading to epidermal 
hyperplasia, a hallmark of psoriasis.
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natural killer T (NKT) cells have been proposed as essential 
players in psoriasis pathogenesis. Thus, further studies will 
have to show if γδ T cells, NK cells, or NKT cells also provide 
potential therapeutic targets for psoriasis.
Traditional therapy
Even without modern knowledge of psoriasis pathogenesis, 
patients have benefited from the constant improvement 
of conventional therapies. Most of the currently accepted 
systemic treatments for psoriasis were developed empiri-
cally or were found by pure chance. However, modern 
knowledge has shed light on the mode of action of some of 
these classic treatments. Fumaric acid and cyclosporine are 
mainly immunosuppressive, retinoids target keratinocytes, 
and methotrexate affects both keratinocytes and immune 
cells.8,50–53 Even though these therapies continue to play an 
important role in psoriasis treatment, they have not fully met 
the needs of patients.54 Although these therapies are effective 
in the majority of patients, potentially serious toxicities can 
in some cases limit their long-term use. Methotrexate has a 
potential for hepatotoxicity and is teratogenic. Cyclosporin 
may lead to impaired renal function and hypertension, 
increased risk of infections, and hypertrichosis. Concerns 
about lymphoma and a potential increase in other malignan-
cies are known adverse effects after long-term treatments. 
Retinoids, which are preferentially used in cases of pustular 
psoriasis, are teratogenic and may lead to dyslipidemia and, 
in rare cases, to hepatotoxic side effects.
Targeted therapy
Over the past 15 years, the increasing knowledge of disease 
pathogenesis has fundamentally changed psoriasis treatment. 
Based on the detailed insight into psoriasis that this increase 
in knowledge has provided, a new generation of therapeutic 
agents, called biologics, has been in development. These 
agents are derived from recombinant DNA technology 
and include monoclonal antibodies and receptor-antibody 
fusion proteins that specifically target the activity of T cells 
or cytokines responsible for the inflammatory nature of the 
disease. By inhibiting specific components of the immune 
system, biologics may not affect cells of other organs, thus 
limiting side effects. Dermatologists have subsequently 
moved from serendipitous choices among the available 
therapeutic options to interventions based on greater insight 
into psoriasis immunopathogenesis. The proof of principle 
of pathogenesis-based therapies in dermatology has created a 
multitude of opportunities for the development of new drugs 
with new therapeutic targets. Indeed, numerous biologics 
are currently moving through different phases of clinical 
development (Table 1) or are already available as therapeutic 
options for patients and doctors.
Tumor necrosis factor (TNF) alpha is a pleiotropic 
cytokine that plays an important role in inflammation 
and is an end-stage product of the inflammatory cytokine 
cascade.55 Indeed, TNF levels are increased in the serum 
and cutaneous plaques of patients with active psoriasis and 
in joints of patients with psoriatic arthritis. Thus, TNF was 
a logical candidate for initial targeted therapies in chronic 
inflammatory diseases such as Crohn’s disease, arthritis, and 
psoriasis. While the first studies were based on anecdotal 
experience with infliximab, a chimeric anti-TNF antibody, 
in a patient with Crohn’s disease and concomitant psoriasis,56 
anti-TNF therapy has become the gold standard for psoriasis 
treatment. Today, several anti-TNF antibodies and fusion 
Table 1 Psoriasis trials: a summary of clinical trials of targeted therapy for psoriasis currently in development
Molecule Mechanism Phase Status Sponsor ClinicalTrials.gov  
identifiera
Indication
iLV-095 Anti-iL-22 i Completed Pfizer NCT01010542 Safety in psoriasis
AIN457 Anti-Th17 ii Completed Novartis NCT00941031 Safety and efficacy in psoriasis
ixekizumab Anti-Th17 iii Recruiting Eli Lilly NCT01646177 Superiority to etanercept
MK3222 Anti-iL-23 iii Recruiting Merck NCT01722331 Safety and efficacy in psoriasis
BT-061 T regulatory cell 
activator
ii Completed Biotest NCT01072383 Safety and efficacy in psoriasis
ACT-128800 S1P1 agonist ii Ongoing Actelion NCT01208090 Safety and efficacy in psoriasis
SCH527123 CXCR2 antagonist ii Completed Schering-Plough NCT00684593 Efficacy in psoriasis
Tofacitinib JAK3 inhibitor ii Approved Pfizer NCT01710046 Efficacy in psoriasis
Ruxolitinib JAK inhibitor ii Completed incyte NCT00820950 Efficacy in psoriasis
ASP015K JAK3 inhibitor ii Completed Astellas Pharma NCT01096862 Efficacy in psoriasis
Apremilast PDE4 inhibitor ii Ongoing Celgene NCT01172938 Efficacy in psoriatic arthritis
AN2728 PDE4 inhibitor ii Completed Anacor Pharmaceuticals NCT01029405 Safety and efficacy in psoriasis
MK0873 PDE4 inhibitor ii Completed Merck NCT01235728 Safety and efficacy in psoriasis
Note: aAll trials are registered under ClinicalTrials.gov and detailed information can be obtained through the ClinicalTrials.gov identifier (NCT number).
Abbreviations: CXCR2, CXC chemokine receptor 2; iL, interleukin; Th, T helper; S1P1, sphingosine-1-phosphate receptor 1; JAK, Janus kinase; PDE4, phosphodiesterase type 4.
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proteins – with diverging efficacies, response onsets, and 
frequencies of side effects57 – are approved for psoriasis 
treatment. Newer anti-TNF compounds such as different 
antibody fragments and antisense nucleotides are in the early 
phases of clinical development.
The recognition of the functional relevance of the 
IFN-IL-23-Th17/Th22 axis in psoriasis pathogenesis led 
to a fast developing group of reagents targeting this axis, 
with ustekinumab as the first approved and broadly used 
antibody of this class.58,59 Ustekinumab targets p40, the 
common subunit of the two heterodimeric cytokines IL-12 
and IL-23, thereby inhibiting both cytokines and their 
ability to drive Th1 and Th17 differentiation, respectively. 
Ustekinumab’s efficacy in patients with moderate to severe 
psoriasis has been shown to be superior to that of etaner-
cept, an anti-TNF fusion protein.60 Briakinumab, another 
anti-IL-12/23 antibody, has shown very impressive response 
in phase III clinical trials.61–63  However, the incidence of 
major adverse cardiovascular events (MACEs) associated 
with briakinumab treatment resulted in the withdrawal 
of its application in 2011. An independent meta-analysis 
was conducted to evaluate a potential association between 
IL-12/23 inhibition and MACEs.64 Although the increased 
rate of MACEs in patients receiving IL-12/23 antibodies 
was not significant, questions about the cardiovascular 
safety of these compounds remain, particularly as low 
IL-17 serum levels have recently been shown to be associ-
ated with a higher risk of MACEs in patients with acute 
myocardial infarction.65 These findings raise further possible 
concerns about the use of inhibitors of the IL-17 pathway in 
clinical settings associated with a high cardiovascular risk. 
Greater detailed insight can be expected from the multitude 
of biologic compounds targeting the IL-23-Th17/Th22 axis 
that are currently in development.
Targeting the subunit p19, which is specific to IL-23, 
has been shown to be efficient in a clinically relevant mouse 
model.27 In addition, blockage of IL-23 but not IL-12 may 
decrease the long-term risk for malignancies, as IL-23 has 
been associated with tumor promotion66 and IL-12 with 
antitumor and antimetastatic activity.67,68 Several specific 
anti-IL-23 agents are currently in clinical and preclinical 
phases of development.
To achieve an even more specific intervention, recent 
research has focused on downstream Th17/Th22 effector 
cytokines, which mediate the adaptive immune response and 
provide the link to epidermal dysregulation in psoriasis. Anti-
IL-22 antibodies are in clinical and preclinical studies, and 
multiple anti-IL-17 and anti-IL-17-receptor inhibitors are 
in development, showing promising clinical results.69–71 
 Furthermore, Th17 cytokines provide potential targets 
for therapeutic interventions, with IL-26 representing 
a very interesting candidate. IL-26 is a member of the 
IL-10 cytokine family and it is significantly upregulated in 
psoriasis.72 Intriguingly, single-nucleotide polymorphisms 
in or near the human IL26 gene have been associated with 
increased risk of developing autoimmune diseases.73–75 
Further studies will have to prove functional relevance for 
IL-26 in the pathogenesis of psoriasis and other auto immune 
diseases, as there is still little known about its biological 
functions.
As with anti-TNF blockers, increased risk for infections 
remains a concern for treatments targeting the IL-23-Th17/
Th22 axis. IL-17 has been shown to play a crucial role for 
host defense against fungi.76,77 Recent findings suggest that 
the IL-23/Th17 axis is a key factor regulating protective 
immunity against opportunistic fungi.78 Ongoing clinical 
trials and national registries will have to show if these agents 
lead to an excess of particularly fungal infections in com-
parison with other immune modulators.
The therapeutic potential of targeting T-cell function in 
psoriasis has been shown by the effective use of efalizumab79 
and alefacept.80 Efalizumab is an anti-CD11a antibody that 
inhibits T-cell activity by disrupting the interaction between 
leukocyte function–associated antigen-1 on T cells and 
intercellular adhesion molecule-1 on antigen-presenting 
cells. Efalizumab also prevents the adhesion of T cells to 
endothelial cells. Therefore, efalizumab blocks T-cell acti-
vation in the lymph node, T-cell trafficking into the skin, 
and reactivation of skin-resident T cells. Efalizumab was 
the first biologic to reach the market for psoriasis, but it was 
finally withdrawn because of a risk of progressive multifo-
cal leukoencephalopathy and other infections. Alefacept is 
a fusion protein that binds to the CD2 receptor expressed on 
T cells, blocking the binding of leukocyte function–associ-
ated antigen-3 on antigen-presenting cells, which provides 
the costimulatory second signal for T-cell activation; thus, 
T-cell activation and proliferation is inhibited. In addition, 
alefacept induces NK cell–mediated apoptosis of memory 
and effector T cells.
Based on these experiences, numerous potential thera-
peutic interventions could be evaluated and, indeed, sev-
eral specific inhibitors of T-cell activation are already in 
development. Like alefacept, the anti-CD2 antibody sipli-
zumab blocks the secondary costimulatory signal necessary 
for T-cell activation. Siplizumab has already been tested in 
clinical trials for psoriasis but it has not shown sufficient 
clinical efficacy.81 On the other hand, anti-CD4 antibodies 
have already been proven to be effective in psoriasis.10,82 CD4 
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is expressed mainly on Th cells and T regulatory cells, but 
it is also expressed on pDCs, cDCs, and monocytes; thus, 
CD4-depleting antibodies are highly immunosuppressive. 
A potentially less immunosuppressive, nondepleting anti-
body is currently in phase II clinical trials for psoriasis and 
rheumatoid arthritis (BT-061, Biotest). Its distinct effects 
on the various immune cells expressing CD4 will have to 
be analyzed, as the functional role of CD4 on dendritic cells 
remains elusive.
During psoriasis pathogenesis, dermal cDCs migrate 
upon stimulation to the draining lymph node where they 
activate T cells, and these T cells in turn enter blood vessels 
and migrate to the skin. Therefore, another potential thera-
peutic option is inhibition of the recruitment of circulating 
immune cells. Recently, lymphocyte egress from second-
ary lymphoid organs and thymus was found to depend on 
sphingosine-1-phosphate receptor 1 within lymphocytes.83,84 
An oral sphingosine-1-phosphate receptor 1 agonist (ACT-
128800, Actelion), currently in clinical development, 
deprives immune cells of this essential signal to egress from 
lymphoid organs and thus leads to the sequestration of T 
cells and reduces the availability of circulating effector T 
cells. Because of its mechanism of action, this novel immu-
nosuppressive drug could be envisioned for the treatment of 
a variety of autoimmune disorders.
While activated cDCs certainly migrate to draining lymph 
nodes to activate T cells, skin-resident immune cells have 
been shown to be sufficient for initiation and maintenance of 
psoriasis.85,86 Based on these findings, treatments should be 
considered for targeting skin-resident immune cells rather than 
systemic components of the immune system. Thus, possible 
future therapeutic options blocking the expansion and survival of 
tissue-resident immune cells might include the inhibition of local 
cytokines and chemokines, blockage of adhesion molecules and 
costimulatory molecules, targeting the skin microenvironment 
and extracellular matrix, and inhibiting emigration of dermal T 
cells into the epidermis. The last of these examples has already 
shown proven efficiency in a clinically relevant xenotrans-
plantation model,14 and antagonists of chemokine receptors 
(SCH527123, Schering-Plough, Kenilworth, New Jersey, USA) 
are currently in phase II clinical trials for psoriasis.
Other therapeutic targets currently being evaluated include 
protein kinase C (PKC) inhibitors, Janus kinase (JAK) inhibi-
tors, mitogen-activated protein kinase inhibitors, and phos-
phodiesterase type 4 (PDE4) inhibitors. PKCs are involved 
in diverse signal transduction pathways that modulate a wide 
variety of cellular events including  activation, proliferation, 
differentiation, apoptosis, and autophagy.  Several PKC 
isoforms play important roles in T-cell-mediated immune 
responses, with PKC theta being essential for T-cell activation 
and IL-2 secretion and PKC beta being relevant for IFN-
gamma production and Th1 responses. Sotrastaurin is the 
first in a new class of selective oral PKC inhibitors that offer 
highly potent inhibition of early T-cell activation.87 Sotrastau-
rin has been tested in clinical trials for transplant rejection 
and psoriasis and has shown promising results.88
The JAK family contains four members, JAK1, JAK2, 
JAK3, and tyrosine kinase 2, which phosphorylate and acti-
vate signal transducers and activators of transcription upon 
activation. JAKs have proven to be important for a multitude 
of immunological processes; they play an essential role in 
various autoimmune diseases and they also promote tumori-
genesis.89,90 The Janus kinase–signal transducer and activa-
tor of transcription pathway is the major signaling cascade 
downstream from cytokine and chemokine receptors. JAK3 
is the only JAK family member that associates with just one 
cytokine receptor subunit, with the common gamma chain, 
which is exclusively used by the receptors for IL-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21. These cytokines are crucial 
for the immune system but not for the function of other 
organs, thus JAK3-specific inhibitors should have limited 
side effects. However, the inhibition of JAK1 and JAK2 has 
also been proven to be beneficial for the treatment of inflam-
matory diseases. Currently, numerous inhibitors of selective 
JAKs or of different JAK family members combined are in 
development for prevention of transplant rejection, treatment 
of psoriasis, rheumatoid arthritis, Crohn’s disease, and for 
various malignancies. Tofacitinib, a pan-JAK inhibitor with 
preference for JAK1 and JAK3, has shown good clinical 
response in psoriasis and is being evaluated as a systemic and 
topical therapy. Ruxolitinib, a specific JAK1/JAK2 inhibi-
tor initially developed for treatment of myeloproliferative 
neoplasms, has been tested as a topical therapy in clinical 
trials for psoriasis. Additionally, a specific JAK3 inhibitor 
(ASP015K, Astellas Pharma, Tokyo, Japan) has entered phase 
III clinical trial for psoriasis.
PDE4 is an enzyme ubiquitously expressed in inflamma-
tory cells that catalyzes the degradation of cyclic adenosine 
monophosphate (cAMP). cAMP is an intracellular second mes-
senger that controls a network of pro- and anti-inflammatory 
mediators. Thus, inhibition of PDE4 leads to an accumulation 
of cAMP and thereby elicits a broad anti-inflammatory effect 
leading to downregulation of TNF, IL-23, and other proinflam-
matory cytokines. Apremilast has shown efficacy in psoria-
sis91 and is currently evaluated mainly in psoriatic arthritis. 
Results from the phase III clinical trial have been made public 
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very recently and have demonstrated clinical efficacy and good 
safety for a treatment duration of 24 weeks. In addition, two 
topical PDE4 inhibitors (AN2728, Anacor Pharmaceuticals, 
Palo Alto, California, USA; MK0873, Merck, Darmstadt, 
Germany) are currently in clinical trials for psoriasis.
Conclusion
As discussed in this review, there are multiple new agents in 
clinical and preclinical development that are showing excit-
ing potential. Of the therapies currently in development, 
agents targeting the IL-23/Th17 axis will most likely have 
the biggest immediate impact when entering the market 
within the next few years. Although IL-22 directly induces 
epidermal hyperproliferation but not IL-17 does not, and 
although functional relevance of IL-22 in psoriasis develop-
ment has been shown in mouse models, IL-17 seems to be 
of greater importance than IL-22 in chronic inflammation 
of psoriasis.29 While initial clinical data on IL-22 inhibition 
in psoriasis have not been very promising, both anti-IL-17 
and anti-IL-17-receptor antibodies have shown excellent 
efficacy in clinical trials. With broad accessibility of IL-17 
blockers after marketing and a growing patient population 
treated with these agents, remaining questions about the 
safety of long-term inhibition of the IL-23/Th17 axis and 
particularly of IL-17 should be addressed: 1) Relevance and 
pathomechanism of the described aggravation of Crohn’s 
disease under anti-IL-17 therapy; 2) the potential association 
of low IL-17 serum levels with a higher risk of MACEs and 
the consequential possible risk of targeting the IL-17 pathway 
in patients with high cardiovascular risk. Nevertheless, anti-
IL-17 antibodies and biologics targeting the IL-23/Th17 axis 
will probably be at the forefront over the next years, together 
with well-established anti-TNF therapy.
In which clinical settings small molecules such as JAK 
inhibitors or PDE4 inhibitors will be used remains to be seen. 
Depending on long-term safety, and largely also on costs 
of these compounds, these small molecules may already 
be used in moderate psoriasis as first-line systemic therapy 
along with methotrexate and fumaric acid, or otherwise in 
more severe disease prior to expensive antibody treatments. 
If costs are similar to currently available biologic agents, 
post-marketing will tell if the benefit of oral availability and 
the clinical efficacy of these small molecules are sufficient 
to gain substantial market share.
In the long run, increasing knowledge of psoriasis patho-
genesis will certainly lead to the emergence of new promis-
ing targets such as IL-21 or IL-26 and, subsequently, to the 
development of additional therapeutic compounds.
Over the past decade, psoriasis has become more and 
more important as a model disease for research in the field 
of chronic inflammation and autoimmunity. Because of 
its easy accessibility and its frequency, psoriasis has also 
become increasingly relevant as a first-choice disease for 
proof-of-concept studies investigating the efficacy of newer 
therapies. Indeed, driven by fundamental and translational 
research, numerous pathogenesis-based therapies are under 
investigation and are currently moving through different 
phases of clinical development.
New insights into psoriasis pathogenesis have already 
led to a multitude of potentially new therapeutic targets. 
Although current biologics are well tolerated, several issues 
such as long-term efficacy, long-term safety, and high costs 
keep driving the search for new and better therapies. With 
further advances in understanding disease pathogenesis, more 
genomic data from psoriasis patients becoming available, 
and potentially the identification of autoantigens in psoriasis, 
current research should lead to the development of a grow-
ing arsenal of improved targeted treatments and to further 
breakthrough immunotherapies.
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